Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
67.72 USD | -0.21% | +2.67% | -16.41% |
Financials (USD)
Sales 2024 * | 27.6B | Sales 2025 * | 27.98B | Capitalization | 84.36B |
---|---|---|---|---|---|
Net income 2024 * | 403M | Net income 2025 * | 6.35B | EV / Sales 2024 * | 3.71 x |
Net Debt 2024 * | 18.15B | Net Debt 2025 * | 12.68B | EV / Sales 2025 * | 3.47 x |
P/E ratio 2024 * |
194
x | P/E ratio 2025 * |
13.1
x | Employees | 18,000 |
Yield 2024 * |
4.57% | Yield 2025 * |
4.79% | Free-Float | 99.89% |
Latest transcript on Gilead Sciences, Inc.
1 day | -0.21% | ||
1 week | +2.67% | ||
Current month | +3.87% | ||
1 month | +1.18% | ||
3 months | -5.39% | ||
6 months | -10.25% | ||
Current year | -16.41% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
13.99% | 254 M€ | +10.97% | - | |
8.10% | 0 M€ | 0.00% | - | |
8.06% | 0 M€ | 0.00% | - | |
5.23% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 67.72 | -0.21% | 3,579,110 |
24-05-16 | 67.86 | +1.27% | 4,831,970 |
24-05-15 | 67.01 | -0.95% | 7,532,064 |
24-05-14 | 67.65 | +0.16% | 4,356,239 |
24-05-13 | 67.54 | +2.40% | 6,736,457 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.41% | 84.36B | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- GILD Stock